Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report
Objective: To describe the case of a patient with Parkinson’s disease (PD) who suffered from a rapid deterioration of his oral health status following treatment…Do Parkinson’s disease medications have an effect on gut microbiome? A case-control study
Objective: To investigate the difference in the gut microbiota between drug-naïve and medicated PD patients and focus on the association between gut microbiota and anti-PD medications. Background:…A neurophysiological profile associated with impulse control disorders in Parkinson’s disease
Objective: To get new insights into the role of oscillatory brain activity recorded non-invasively in patients with Parkinson’s disease (PD) and impulse control disorders (ICDs).…Quality of Life Study of Patients Living with Parkinson’s Disesae in Sub-Saharan Africa
Objective: The objective is to assess the quality of life of patients with Parkinson's disease followed in Senegal. Background: Parkinson's disease is a neurodegenerative disease,…Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?
Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…Claims Data Analysis of Parkinson’s Disease Medication Utilization
Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…Epidemiology of Impulse Control Disorders and Association with Dopamine Agonist Exposure in the United States Military
Objective: Evaluate the epidemiology of impulse control disorders in the US Military and their association with dopamine agonist exposure. Background: Impulse control disorders (ICDs) are…Frequency and risk factors of dopamine agonist-induced peripheral edema in patients with Parkinson’s disease
Objective: To determine the frequency and risk factors of peripheral edema (PE) development and whether discontinuation of the drug is enough for treatment. To determine…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 13
- Next Page »